Cargando…

A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk

BACKGROUND: Low concentration C‐reactive protein (CRP) has favorable prognostic significance in patients with cardiovascular risks. METHODS: We compared the wr‐CRP method with the hs‐CRP method both on Roche Cobas c702 analyzer for the determination of low CRP concentration (<20 mg/L) including 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Runqing, Xue, Yajun, Wang, Tengjiao, Gong, Lijun, Peng, Peng, Xiong, Pan, Dai, Mingzhu, Shao, Tongju, Hu, Yuhan, Ye, Xinchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805322/
https://www.ncbi.nlm.nih.gov/pubmed/31218740
http://dx.doi.org/10.1002/jcla.22957
_version_ 1783461355205951488
author Li, Runqing
Xue, Yajun
Wang, Tengjiao
Gong, Lijun
Peng, Peng
Xiong, Pan
Dai, Mingzhu
Shao, Tongju
Hu, Yuhan
Ye, Xinchen
author_facet Li, Runqing
Xue, Yajun
Wang, Tengjiao
Gong, Lijun
Peng, Peng
Xiong, Pan
Dai, Mingzhu
Shao, Tongju
Hu, Yuhan
Ye, Xinchen
author_sort Li, Runqing
collection PubMed
description BACKGROUND: Low concentration C‐reactive protein (CRP) has favorable prognostic significance in patients with cardiovascular risks. METHODS: We compared the wr‐CRP method with the hs‐CRP method both on Roche Cobas c702 analyzer for the determination of low CRP concentration (<20 mg/L) including 200 patients treated in Cardiology Department in Beijing Tsinghua Changgung Hospital (Beijing, China) from December 2018 to March 2019. RESULTS: The two methods were highly correlated (Spearman's rho = 0.995). Deming regression was used to fit the regression analysis model, giving a slope of 1.058 with an intercept of 0.008. The median method difference (wr‐CRP − hr‐CRP) was 0.120 mg/L (95% CI, 0.086‐0.200 mg/L), and the median percent differences were 7.34% (95% CI, 4.27%‐8.47%). The percent bias between both methods at the given cutoff CRP values of 1, 3, and 10 mg/L evaluated by Deming regression was 6.60%, 6.07%, and 5.88%, respectively, all of which were less than the acceptable standard (12.50%). The percentage of sample results concordant by both methods for the risk stratification was 96.0% (kappa = 0.937, P < 0.001). CONCLUSIONS: Roche wr‐CRP and hs‐CRP assays are highly concordant in determining low concentration CRP. Wr‐CRP may be used as an alternative to hs‐CRP assay on Roche Cobas c702 analyzer to assess the cardiovascular risk, considering its convenience and lower costs.
format Online
Article
Text
id pubmed-6805322
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68053222019-11-12 A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk Li, Runqing Xue, Yajun Wang, Tengjiao Gong, Lijun Peng, Peng Xiong, Pan Dai, Mingzhu Shao, Tongju Hu, Yuhan Ye, Xinchen J Clin Lab Anal Research Articles BACKGROUND: Low concentration C‐reactive protein (CRP) has favorable prognostic significance in patients with cardiovascular risks. METHODS: We compared the wr‐CRP method with the hs‐CRP method both on Roche Cobas c702 analyzer for the determination of low CRP concentration (<20 mg/L) including 200 patients treated in Cardiology Department in Beijing Tsinghua Changgung Hospital (Beijing, China) from December 2018 to March 2019. RESULTS: The two methods were highly correlated (Spearman's rho = 0.995). Deming regression was used to fit the regression analysis model, giving a slope of 1.058 with an intercept of 0.008. The median method difference (wr‐CRP − hr‐CRP) was 0.120 mg/L (95% CI, 0.086‐0.200 mg/L), and the median percent differences were 7.34% (95% CI, 4.27%‐8.47%). The percent bias between both methods at the given cutoff CRP values of 1, 3, and 10 mg/L evaluated by Deming regression was 6.60%, 6.07%, and 5.88%, respectively, all of which were less than the acceptable standard (12.50%). The percentage of sample results concordant by both methods for the risk stratification was 96.0% (kappa = 0.937, P < 0.001). CONCLUSIONS: Roche wr‐CRP and hs‐CRP assays are highly concordant in determining low concentration CRP. Wr‐CRP may be used as an alternative to hs‐CRP assay on Roche Cobas c702 analyzer to assess the cardiovascular risk, considering its convenience and lower costs. John Wiley and Sons Inc. 2019-06-20 /pmc/articles/PMC6805322/ /pubmed/31218740 http://dx.doi.org/10.1002/jcla.22957 Text en © 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Li, Runqing
Xue, Yajun
Wang, Tengjiao
Gong, Lijun
Peng, Peng
Xiong, Pan
Dai, Mingzhu
Shao, Tongju
Hu, Yuhan
Ye, Xinchen
A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk
title A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk
title_full A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk
title_fullStr A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk
title_full_unstemmed A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk
title_short A comparison study between wide‐range and high‐sensitivity C‐reactive protein assays (Roche Cobas c702) for low C‐reactive protein concentration in patients with cardiovascular risk
title_sort comparison study between wide‐range and high‐sensitivity c‐reactive protein assays (roche cobas c702) for low c‐reactive protein concentration in patients with cardiovascular risk
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805322/
https://www.ncbi.nlm.nih.gov/pubmed/31218740
http://dx.doi.org/10.1002/jcla.22957
work_keys_str_mv AT lirunqing acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT xueyajun acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT wangtengjiao acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT gonglijun acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT pengpeng acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT xiongpan acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT daimingzhu acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT shaotongju acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT huyuhan acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT yexinchen acomparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT lirunqing comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT xueyajun comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT wangtengjiao comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT gonglijun comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT pengpeng comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT xiongpan comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT daimingzhu comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT shaotongju comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT huyuhan comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk
AT yexinchen comparisonstudybetweenwiderangeandhighsensitivitycreactiveproteinassaysrochecobasc702forlowcreactiveproteinconcentrationinpatientswithcardiovascularrisk